Viyash Scientific (VIYASH) AI Stock Analysis

Top Page

Viyash Scientific

(NSE:VIYASH)

Select Model

Rating:59Neutral

Price Target:INR 228.00▲(4.35% Upside)

Action:reiterated

Date:08/21/26

The score is driven primarily by improving financial performance, including a sharp profitability rebound and significantly stronger leverage position, but is capped by weaker cash conversion and prior volatility in results. Technicals are neutral with modestly negative momentum near-term, and valuation is a key headwind due to the very high P/E.

Positive Factors

Revenue and Profitability ReboundRevenue more than doubled year over year in 2026 while profitability strengthened after losses, indicating a substantial operating rebound. If sustained, this broader revenue base can support reinvestment and improve earnings capacity over the next several quarters.

Negative Factors

Profitability VolatilityProfitability was negative in 2023–2024, and margins have remained volatile, including a low net margin in 2025. The rebound is encouraging, but inconsistent historical earnings make it harder to assume that current margins will persist through the next several quarters.

Viyash Scientific (VIYASH) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 101.88B
Dividend Yield: ―
Average Volume (3M): 364.95K
Price to Earnings (P/E): 52.1
Beta (1Y): 1.20
Revenue Growth: 96.48%
EPS Growth: 251.87%
Country: India
Employees: 1,244
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Viyash Scientific Business Overview & Revenue Model

Company Description

Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, incl...

Viyash Scientific Financial Statement Overview

Summary

Financials show a strong rebound: profitability turned meaningfully positive in 2025 and strengthened in 2026 alongside dramatic revenue acceleration and improved EBIT/EBITDA margins. The balance sheet improved materially with much lower leverage (debt-to-equity ~0.17 in 2026) and expanding equity. The main offset is quality/consistency risk: margins were volatile with loss years in 2023–2024, and cash conversion remains modest with free cash flow still well below net income and a history of weak/negative FCF (2022–2024).

Income Statement

68Positive

Balance Sheet

78Positive

Cash Flow

58Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	31.49B	34.20B	15.51B	13.66B	14.18B	14.10B
Gross Profit	10.67B	10.58B	7.40B	5.53B	1.59B	5.66B
EBITDA	5.84B	6.54B	1.59B	549.80M	-464.48M	1.18B
Net Income	1.71B	1.77B	218.80M	-358.69M	-1.21B	409.55M
Balance Sheet
Total Assets	0	46.28B	16.02B	15.40B	15.29B	14.51B
Cash, Cash Equivalents and Short-Term Investments	2.59B	2.70B	632.04M	687.85M	416.25M	591.21M
Total Debt	0	4.90B	4.81B	4.88B	4.44B	3.65B
Total Liabilities	-31.15B	15.14B	8.32B	8.27B	7.80B	7.11B
Stockholders Equity	31.15B	29.11B	7.04B	6.57B	6.99B	6.92B
Cash Flow
Free Cash Flow	288.00M	1.29B	442.70M	-2.12M	-693.71M	-18.69M
Operating Cash Flow	449.00M	2.64B	833.60M	305.95M	168.08M	305.95M
Investing Cash Flow	-42.20M	-938.90M	-247.80M	-119.05M	-649.58M	-955.66M
Financing Cash Flow	-325.70M	-543.10M	-607.30M	45.46M	322.28M	672.57M

Viyash Scientific Technical Analysis

Technical Analysis SentimentNegative

Last Price218.50

Price Trends

50DMA244.34Negative

100DMA255.07Negative

200DMA233.47Negative

Market Momentum

MACD-7.64Negative

RSI41.75Neutral

STOCH74.52Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIYASH, the sentiment is Negative. The current price of 218.50 is below the 20-day moving average (MA) of 225.09, below the 50-day MA of 244.34, and below the 200-day MA of 233.47, indicating a bearish trend. The MACD of -7.64 indicates Negative momentum. The RSI at 41.75 is Neutral, neither overbought nor oversold. The STOCH value of 74.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIYASH.

Viyash Scientific Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:VIYASH against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:ALIVUS	86Outperform	INR 172.84B	28.81	―	0.36%	8.19%	26.12%
IN:CAPLIPOINT	85Outperform	INR 176.72B	26.57	―	0.34%	15.01%	17.73%
IN:STAR	74Outperform	INR 98.55B	15.97	―	0.47%	11.28%	55.18%
IN:AKUMS	73Outperform	INR 115.20B	38.41	―	0.41%	9.18%	-14.57%
IN:APLLTD	70Outperform	INR 156.82B	22.62	―	1.50%	14.12%	14.98%
IN:VIYASH	59Neutral	INR 96.44B	52.12	―	―	96.48%	251.87%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:VIYASH and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:VIYASH	Viyash Scientific Limited	218.50	0.55	0.25%
IN:AKUMS	Akums Drugs and Pharmaceuticals Limited	731.90	265.86	57.05%
IN:APLLTD	Alembic Pharmaceuticals Limited	797.80	-112.95	-12.40%
IN:CAPLIPOINT	Caplin Point Laboratories Limited	2324.85	325.80	16.30%
IN:ALIVUS	Glenmark Life Sciences Limited	1407.80	494.61	54.16%
IN:STAR	Strides Pharma Science Ltd	1069.15	89.49	9.13%

Viyash Scientific Corporate Events

Viyash Scientific Publishes Q1 FY’27 Earnings Call Transcript for Investors

Aug 16, 2026

Viyash Scientific Limited has notified stock exchanges about the availability of its Q1 FY’27 earnings call transcript for the quarter ended June 30, 2026. The disclosure, made under Regulation 30 of India’s listing obligations framework,...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 21, 2026

Viyash Scientific AI Stock Analysis

Top Page